BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) VP Alane P. Barnes sold 44,290 shares of the company’s stock in a transaction on Friday, November 30th. The stock was sold at an average price of $9.07, for a total transaction of $401,710.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

BioCryst Pharmaceuticals stock opened at $8.95 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.98 and a current ratio of 2.00. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.25 and a twelve month high of $9.70.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03). The business had revenue of $1.45 million during the quarter, compared to the consensus estimate of $2.53 million. BioCryst Pharmaceuticals had a negative return on equity of 141.00% and a negative net margin of 428.00%. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Several analysts have weighed in on BCRX shares. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, August 13th. They noted that the move was a valuation call. BidaskClub raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 10th. Jefferies Financial Group reissued a “buy” rating and issued a $8.50 price target on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 9th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 15th. Finally, JMP Securities boosted their price target on shares of BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $11.41.

Several large investors have recently modified their holdings of the company. American International Group Inc. raised its stake in shares of BioCryst Pharmaceuticals by 12.8% during the third quarter. American International Group Inc. now owns 72,390 shares of the biotechnology company’s stock valued at $552,000 after acquiring an additional 8,236 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 4.1% during the third quarter. Teachers Advisors LLC now owns 294,786 shares of the biotechnology company’s stock valued at $2,249,000 after acquiring an additional 11,682 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of BioCryst Pharmaceuticals by 3.1% during the third quarter. Bank of New York Mellon Corp now owns 420,825 shares of the biotechnology company’s stock valued at $3,211,000 after acquiring an additional 12,544 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at about $122,000. Finally, Warren Averett Asset Management LLC bought a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at about $171,000. 91.34% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) VP Sells $401,710.30 in Stock” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/biocryst-pharmaceuticals-inc-bcrx-vp-sells-401710-30-in-stock/2666818.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Featured Article: Using the New Google Finance Tool

Insider Buying and Selling by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.